A large study suggests the cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound can disappear surprisingly quickly when treatment stops. After two years off the medications, patients had a 22% higher risk of heart attack, stroke, and death compared with those who stayed on them.
A recent study conducted by the University of Washington in St. Louis reveals that discontinuation of treatment with GLP-1 drugs, such as Ozempic, can significantly increase the risk of cardiovascular events, such as heart attack and...